AI assistant
FENNEC PHARMACEUTICALS INC. — Director's Dealing 2018
Feb 9, 2018
35599_dirs_2018-02-08_0ba72e2a-c3e1-41c6-944e-6c2b2d7ebdbf.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: FENNEC PHARMACEUTICALS INC. (FENC)
CIK: 0001211583
Period of Report: 2018-02-06
Reporting Person: Andrade Robert (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-02-06 | Stock Option (right to buy) | $8.38 | A | 50000 | Acquired | 2025-02-06 | Common Shares (50000) | Direct |
Footnotes
F1: On February 6,, 2018, Robert Andrade was granted an incentive stock option to purchase 500,000 shares of the Issuer's common shares pursuant to the Issuer's Amended and Restated Stock Option Plan.
F2: 1/3 of the shares subject to this option shall vest immediately and may be exercised as of February 6, 2019 (the "Vesting Commencement Date"). 1/24 of the shares subject to this option shall vest immediately and may be exercised as of the last day of each month following the Vesting Commencement Date. As of February 6, 2021 and thereafter, 100% of the total number of shares subject to this option shall be vested.